U.S. data show rising 'breakthrough' infections among fully vaccinated
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Pfizer (PFE) and BioNTech(BTNX) Partner With Eurofarma Laboratórios to Manufacture COVID-19 Vaccine in Latin America
August 26, 2021 6:47 AM EDTPfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufacture COMIRNATY® (COVID-19 Vaccine, mRNA) for distribution within Latin America.
Eurofarma will perform manufacturing activities within Pfizers and BioNTechs global COVID-19 vaccine supply chain and manufacturing network, which will now span four continents and include more than 20 manufacturing facilities. To facilitate Eurofarmas involvement in the process, technical transfer, on-site development, and equipment installation activities will begin immediately.... More
Moderna, Inc’s (MRNA) Vaccine’s FDA Approval Could Lead to Greater Market Share in Coming Years - Analyst
August 25, 2021 1:09 PM EDTEarlier today, Moderna, Inc. (Nasdaq: MRNA) announced it has completed the rolling submission process for its Biologics... More
Taiwan to get BioNTech (BNTX) shots early as China Delays Approval -source - Reuters News
August 25, 2021 6:17 AM EDTTaiwan to get BioNTech SE (NASDAQ: BNTX)shots early as China delays approval-source - Reuters News
... More